Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06647732 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT)

StatusActive, Not Recruiting
PhasePhase 2
Started2024-10-30
View on ClinicalTrials.gov ↗

Amendment history

2026-09-16
Enrollment closed, study ongoing
Primary completion moved earlier: 2028-08-31 → 2026-12-31
2026-01-13
Study Identification, Study Status, Oversight v2
Study titlerevised
Zanubrutinib Plus Rituximab Asas Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT)
2025-03-11
Study Status v1
Start dateestimated 2024-10-25→confirmed 2024-10-30
2024-10-16
Original filing
This is a prospective, single-arm, multicenter, phase II clinical trial to evaluate the efficacy and safety of Zanubrutinib in combination with Rituximab as a first-line treatment for patients with mucosa-associated lymphoid tissue (MALT) extranodal marginal zone lymphoma.
Trial Details
NCT Number NCT06647732
Lead Sponsor Sun Yat-sen University
Collaborators: Fifth Affiliated Hospital, Sun Yat-Sen University, Gansu Cancer Hospital, Fifth Affiliated Hospital of Guangzhou Medical University, Beijing Tongren Hospital, Huazhong University of Science and Technology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Shenzhen People's Hospital
Conditions Mucosa-associated Lymphoid Tissue Lymphoma (MALT)
Enrollment 42 participants
Start Date 2024-10-30
Primary Completion 2026-12-31 (estimated)
Study Completion 2028-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-09-15